Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CXCL5/ENA-78 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB654SP
This item is not returnable.
View return policy
Description
CXCL5/ENA-78 Monoclonal specifically detects CXCL5/ENA-78 in Human samples. It is validated for Neutralization, Intracellular Staining by Flow Cytometry, CyTOF-ready, ELISA Capture (Matched Antibody Pair).Specifications
CXCL5/ENA-78 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
chemokine (C-C motif) ligand 5, C-X-C motif chemokine 5, CXCL5, ENA78, ENA-78, ENA-78(1-78), Epithelial-derived neutrophil-activating protein 78, Neutrophil-activating peptide ENA-78, neutrophil-activating protein 78, SCYB5ENA78 | |
Mouse | |
Protein A or G purified from ascites | |
RUO | |
6374 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Neutralization, Flow Cytometry, CyTOF, ELISA | |
33170 | |
Neutralization 0.65 to 5 μg/mL, Intracellular Staining by Flow Cytometry 0.25 μg/10^6 cells, CyTOF-ready, ELISA Capture (Matched Antibody Pair) 2 to 8 μg/mL | |
P42830 | |
CXCL5 | |
E. coli-derived recombinant human CXCL5/ENA-78 Ala37-Asn114 Accession # P42830 | |
25 μg | |
Primary | |
Detects human CXCL5/ENA-78 in ELISAs. Does not cross-react with recombinant human CXCL1, 2, or 3. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction